Rockwell Medical (RMTI) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 08, 2020
Document and Entity Information
Entity Registrant Name	ROCKWELL MEDICAL, INC.
Entity Central Index Key	0001041024
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding (in shares)		69,069,078
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2020	Dec. 31, 2019
ASSETS
Cash and Cash Equivalents	$ 37,399,801	$ 11,794,526
Investments Available-for-Sale	11,456,285	14,250,176
Accounts Receivable, net	4,586,748	4,202,725
Inventory	4,292,768	3,646,906
Prepaid and Other Current Assets	1,758,002	2,979,504
Total Current Assets	59,493,604	36,873,837
Property and Equipment, net	2,430,113	2,433,405
Inventory, Non-Current	623,000	441,000
Right of Use Assets, net	2,797,759	3,212,530
Goodwill	920,745	920,745
Other Non-Current Assets	560,588	434,935
Total Assets	66,825,809	44,316,452
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	3,123,181	3,018,424
Accrued Liabilities	6,160,047	4,517,732
Settlement Payable	57,000	104,000
Lease Liability - Current	1,351,348	1,493,394
Deferred License Revenue - Current	2,179,383	2,233,640
Insurance Financing Note Payable	190,855	763,422
Customer Deposits	146,831	55,100
Other Current Liability - Related Party	148,523	187,849
Total Current Liabilities	13,357,168	12,373,561
Lease Liability - Long-Term	1,559,749	1,780,626
Term Loan, Net of Issuance Costs	20,683,704	0
Deferred License Revenue - Long-Term	9,450,983	9,842,762
Total Liabilities	45,051,604	23,996,949
Commitments and Contingencies (See Note 16)
Stockholders’ Equity:
Preferred Stock, $0.0001 par value, no shares issued and outstanding at March 31, 2020 and December 31, 2019	0	0
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 69,049,102 and 65,378,890 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	6,905	6,538
Additional Paid-in Capital	336,216,422	326,777,250
Accumulated Deficit	(314,500,003)	(306,516,265)
Accumulated Other Comprehensive Income	50,881	51,980
Total Stockholders’ Equity	21,774,205	20,319,503
Total Liabilities And Stockholders’ Equity	$ 66,825,809	$ 44,316,452

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred shares, shares issued (in shares)	0	0
Preferred shares, shares outstanding (in shares)	0	0
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common shares, shares authorized (in shares)	170,000,000	170,000,000
Common Shares, shares issued (in shares)	69,049,102	65,378,890
Common Shares, shares outstanding (in shares)	69,049,102	65,378,890

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net Sales	$ 15,856,539	$ 15,559,439
Cost of Sales	14,743,613	14,549,047
Gross Profit	1,112,926	1,010,392
Selling and Marketing	2,072,798	3,102,378
General and Administrative	5,273,433	6,220,499
Research and Product Development	1,821,488	497,276
Operating Loss	(8,054,793)	(8,809,761)
Other Income (Expense)
Realized Gain on Investments	1,929	13,888
Interest Expense	(101,951)	0
Interest Income	171,077	117,526
Total Other Income	71,055	131,414
Net Loss	$ (7,983,738)	$ (8,678,347)
Basic and Diluted Net Loss per Share (in dollars per share)	$ (0.12)	$ (0.15)
Basic and Diluted Weighted Average Shares Outstanding (in shares)	67,518,240	57,098,947

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net Loss	$ (7,983,738)	$ (8,678,347)
Unrealized Loss on Available-for-Sale Debt Instrument Investments	(6,710)	(7,161)
Foreign Currency Translation Adjustments	5,611	(92)
Comprehensive Loss	$ (7,984,837)	$ (8,685,600)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Total	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT	ACCUMULATED OTHER COMPREHENSIVE INCOME
Beginning balance (in shares) at Dec. 31, 2018		57,034,154
Beginning balance at Dec. 31, 2018	$ 27,276,874	$ 5,703	$ 299,596,257	$ (272,388,234)	$ 63,148
Increase (Decrease) in Shareholders' Equity
Net Loss	(8,678,347)			(8,678,347)
Unrealized Loss on Available-for-Sale Investments	(7,161)				(7,161)
Foreign Currency Translation Adjustments	(92)				(92)
Exercise of Employee Stock Options, Net of Tax (in shares)		30,000
Exercise of Employee Stock Options, Net of Tax	147,900	$ 3	147,897
Delivery of common stock underlying restricted stock units, net of tax (in shares)		64,173
Delivery of common stock underlying restricted stock units, net of tax	(95,429)	$ 7	(95,436)
Stock-based Compensation	1,517,302		1,517,302
End balance (in shares) at Mar. 31, 2019		57,128,327
End balance at Mar. 31, 2019	20,161,047	$ 5,713	301,166,020	(281,066,581)	55,895
Beginning balance (in shares) at Dec. 31, 2018		57,034,154
Beginning balance at Dec. 31, 2018	$ 27,276,874	$ 5,703	299,596,257	(272,388,234)	63,148
Increase (Decrease) in Shareholders' Equity
Issuance of common stock, net of offering costs/Bought Deal (in shares)	1,840,443
End balance (in shares) at Dec. 31, 2019	65,378,890	65,378,890
End balance at Dec. 31, 2019	$ 20,319,503	$ 6,538	326,777,250	(306,516,265)	51,980
Increase (Decrease) in Shareholders' Equity
Net Loss	(7,983,738)			(7,983,738)
Unrealized Loss on Available-for-Sale Investments	(6,710)				(6,710)
Foreign Currency Translation Adjustments	5,611				5,611
Issuance of common stock, net of offering costs/Bought Deal (in shares)		3,670,212
Issuance of common stock, net of offering costs/Bought Deal	8,003,957	$ 367	8,003,590
Issuance of Warrants related to Debt Financing	500,736		500,736
Stock-based Compensation	$ 934,846		934,846
End balance (in shares) at Mar. 31, 2020	69,049,102	69,049,102
End balance at Mar. 31, 2020	$ 21,774,205	$ 6,905	$ 336,216,422	$ (314,500,003)	$ 50,881

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Cash Flows From Operating Activities:
Net Loss	$ (7,983,738)	$ (8,678,347)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	209,367	187,527
Stock-based Compensation	934,846	1,517,302
Increase in Inventory Reserves	0	11,000
Amortization of Right of Use Asset	390,517	478,442
Amortization of Debt Financing Costs and Accretion of Debt Discount	15,262	0
Realized (Gain) on Sale of Investments Available-for-Sale	(1,929)	(13,888)
Foreign Currency Translation Adjustment	5,611	(92)
Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable, net	(384,024)	268,104
Decrease in Insurance Receivable	0	371,217
(Increase) Decrease in Inventory	(827,861)	162,208
Decrease in Prepaid and Other Assets	1,092,529	203,982
Increase in Accounts Payable	104,757	30,154
Decrease in Settlement Payable	(47,000)	(249,999)
Decrease in Lease Liability	(338,668)	(467,440)
Increase in Other Liabilities	737,937	1,319,375
Decrease in Deferred License Revenue	(446,036)	(563,217)
Changes in Assets and Liabilities	(108,366)	1,074,384
Cash Used In Operating Activities	(6,538,430)	(5,423,672)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale	(8,871,583)	(8,812,954)
Sale of Investments Available-for-Sale	11,660,692	12,761,519
Purchase of Equipment	(202,753)	(121,826)
Purchase of Research and Development Licenses (Related Party)	0	(250,000)
Cash Provided By Investing Activities	2,586,356	3,576,739
Cash Flows From Financing Activities:
Proceeds from Term Loan	22,500,000	0
Debt Issuance Costs	(374,043)	0
Payments on Short Term Note Payable	(572,566)	0
Proceeds from the Issuance of Common Stock / Public Offering	8,147,871	0	$ 5,383,079
Offering Costs from the Issuance of Common Stock / Public Offering	(143,913)	0	(309,479)
Proceeds from the Exercise of Employee Stock Options	0	147,900
Repurchase of Common Shares to Pay Employee Withholding Taxes	0	(95,429)
Cash Provided By Financing Activities	29,557,349	52,471
Increase (Decrease) In Cash and Cash Equivalents	25,605,275	(1,794,462)
Cash At Beginning Of Period	11,794,526	22,713,980	22,713,980
Cash At End Of Period	37,399,801	20,919,518	$ 11,794,526
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest	80,908	0
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale	(6,710)	(7,161)
Delivery of Common Stock Underlying Restricted Stock Units	0	273,830
Issuance Costs related to Debt Financing, not yet paid	956,782	0
Fair Value of Warrants issued related to Debt Financing	$ 500,736	$ 0

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Rockwell Medical, Inc. and subsidiaries (collectively, “we”, “our”, “us”, or the “Company”), is a biopharmaceutical company dedicated to improving outcomes for patients with iron-deficiency anemia, with an initial focus on patients with end-stage renal disease (ESRD) and on dialysis. The Company is focused on developing its proprietary ferric pyrophosphate (“FPC”) therapeutic platform, and the first product developed from this platform is Triferic, the first-FDA approved product for the replacement of iron and maintenance of hemoglobin in adult hemodialysis patients. We initiated commercial sales of Triferic Dialysate, during the second quarter of 2019 and received approval by the U.S. Food and Drug Administration ("FDA") for the intravenous formulation of Triferic, Triferic AVNU, on March 27, 2020. We plan to leverage our experience with Triferic to develop our FPC platform for iron deficiency and iron deficiency anemia in other disease states. We are also a manufacturer of hemodialysis concentrates for dialysis providers and distributors in the United States and abroad. We supply the domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim. Our mission is to transform anemia management in a wide variety of disease states across the globe while improving patients’ lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of dialysis. Triferic® is a registered trademark of Rockwell Medical, Inc.

Liquidity and Capital Resources

Liquidity and Capital Resources	3 Months Ended
	Mar. 31, 2020
Liquidity and Capital Resources
Liquidity and Capital Resources	Liquidity and Capital Resources As of March 31, 2020 , the Company had approximately $37.4 million of cash and cash equivalents, $11.5 million of investments available-for-sale, working capital of $46.1 million and an accumulated deficit of $314.5 million . Net cash used in operating activities for the three months ended March 31, 2020 was approximately $6.5 million . Management evaluated the Company’s ability to continue as going concern for at least the next 12 months from the filing of this report. Based on the currently available working capital, capital raise and debt financing described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report. In February 2020, the Company sold 3,670,212 shares of its common stock for proceeds of $8.0 million , net of issuance costs. On March 16, 2020, the Company closed a debt financing transaction with net proceeds at closing of approximately $21.2 million , net of fees and expenses (See Note 17 for further detail). The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the continued commercialization of Triferic Dialysate and Triferic AVNU, which was approved by the FDA in March 2020, executing plans for enhancing its medical capabilities, generating additional data for Triferic and developing Triferic for new therapeutic indications. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results. The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2020 or for any future interim period. The condensed consolidated balance sheet at March 31, 2020 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2019 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2019 and notes thereto included in the Company’s Annual Report on Form 10-K filed on March 17, 2020. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. The Company continues to account for leases in the prior period financial statements in accordance with ASC Topic 840. Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of March 31, 2020 2019 Options to purchase common stock 8,191,963 8,289,605 Unvested restricted stock awards 146,800 146,800 Unvested restricted stock units 1,461,588 1,461,917 Warrants to purchase common stock 3,248,054 — 13,048,405 9,898,322 Adoption of Recent Accounting Pronouncements The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: • Step 1: Identify the contract with the customer • Step 2: Identify the performance obligations in the contract • Step 3: Determine the transaction price • Step 4: Allocate the transaction price to the performance obligations in the contract • Step 5: Recognize revenue when the company satisfies a performance obligation Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer. Nature of goods and services The following is a description of principal activities from which the Company generates its revenue. Product sales – The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach. Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales. For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales. In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer. The Company received upfront fees under three distribution and license agreements that have been deferred as a contract liability. The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”) and Sun Pharmaceutical Industries Ltd. ("Sun Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China and India, respectively, to determine that regulatory approval was probable as of the execution of the agreement. The amounts received from Baxter Healthcare Corporation (“Baxter”), are recognized as revenue at the point in time that the estimated product sales under the agreement occur. For the business under the Company’s distribution agreement with Baxter (the “Baxter Agreement”), and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days , while distributor payment terms average 45 days . Disaggregation of revenue Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended March 31, 2020 Products By Geographic Area Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 199 $ 199 $ — License Fee – Over time 56 — 56 Total Drug Products 255 199 56 Concentrate Products Product Sales – Point-in-time 15,112 13,506 1,606 License Fee – Over time 490 490 — Total Concentrate Products 15,602 13,996 1,606 Net Revenue $ 15,857 $ 14,195 $ 1,662 Three Months Ended March 31, 2019 Products By Geographic Area Total U.S. Rest of World Drug Revenues License Fee – Over time $ 68 $ — 68 Total Drug Products 68 — 68 Concentrate Products Product Sales – Point-in-time 14,996 12,923 2,073 License Fee – Over time 495 495 — Total Concentrate Products 15,491 13,418 2,073 Net Revenue $ 15,559 $ 13,418 $ 2,141 Contract balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of US dollars ($) March 31, 2020 December 31, 2019 Receivables, which are included in "Trade and other receivables" $ 4,587 $ 4,203 Contract liabilities $ 11,630 $ 12,076 There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three months ended March 31, 2020 and 2019 . For the three months ended March 31, 2020 and March 31, 2019 , the Company did not recognize material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of March 31, 2020 and December 31, 2019 . The Company does not generally accept returns of its concentrate products and no reserve for returns of concentrate products was established as of March 31, 2020 or December 31, 2019 . The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products Transaction price allocated to remaining performance obligations For the three months ended March 31, 2020 , revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $11.6 million as of March 31, 2020 . The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled performance obligations related to the Baxter Agreement are product sales of $8.6 million , which will be amortized through expiration of the Baxter Agreement on October 2, 2024.

Investments - Available-for-Sal

Investments - Available-for-Sale	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Investments - Available-for-Sale	Investments - Available-for-Sale Investments available-for-sale consisted of the following as of March 31, 2020 and December 31, 2019 : March 31, 2020 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Income Fair Value Available-for-Sale Securities Bonds $ 11,385,053 $ 22,356 $ (10,789 ) $ 59,665 $ 11,456,285 December 31, 2019 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 14,238,161 $ 13,321 $ (1,306 ) $ — $ 14,250,176 The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as Level 1, as described in Note 3, Fair Value Measurement to our condensed consolidated financial statements. As of March 31, 2020 and December 31, 2019 , the amortized cost and estimated fair value of our available-for-sale securities were due within one year.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory	Inventory Components of inventory, net of reserves as of March 31, 2020 and December 31, 2019 are as follows: March 31, December 31, Raw Materials $ 2,750,185 $ 2,471,234 Work in Process 291,697 184,382 Finished Goods 1,873,886 1,432,290 Total $ 4,915,768 $ 4,087,906 As of March 31, 2020 , we classified $0.6 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of March 31, 2020 , we had total Triferic inventory aggregating $3.4 million , against which we had reserved $2.4 million . The $1.0 million net value of Triferic inventory consisted of $0.2 million of Triferic Dialysate finished goods with expiration dates ranging from June 2020 to May 2021, $0.5 million of Triferic API with estimated remaining shelf life extending through 2023, and $0.3 million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.

Property And Equipment

Property And Equipment	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment As of March 31, 2020 and December 31, 2019 , the Company’s property and equipment consisted of the following: March 31, December 31, Leasehold Improvements $ 1,175,986 $ 1,162,328 Machinery and Equipment 4,833,654 4,672,724 Information Technology & Office Equipment 1,810,246 1,810,246 Laboratory Equipment 652,676 653,075 8,472,562 8,298,373 Accumulated Depreciation (6,042,449 ) (5,864,968 ) Net Property and Equipment $ 2,430,113 $ 2,433,405 Depreciation expense for the three months ended March 31, 2020 and 2019 , totaled $0.2 million and $0.2 million , respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Accrued Research & Development Expense $ 227,152 $ 283,407 Accrued Compensation and Benefits 1,920,577 1,018,196 Accrued Legal Expenses 339,606 181,597 Accrued Marketing Expenses 129,936 61,164 Other Accrued Liabilities 3,542,776 2,973,368 Total Accrued Liabilities $ 6,160,047 $ 4,517,732

Insurance Financing Note Payabl

Insurance Financing Note Payable	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Insurance Financing Note Payable	Insurance Financing Note Payable On June 3, 2019, the Company entered into a short-term note payable for $1.9 million , bearing interest at 4.65% per annum to finance various insurance policies. Principal and interest payments related to this note will begin on July 3, 2019 and are paid on a straight-line amortization over a 10 -month period with the final payment due on April 3, 2020. As of March 31, 2020 , the Company’s insurance note payable balance was $0.2 million . Loan and Security Agreement On March 16, 2020 , Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including the FDA approval of the Company’s New Drug Application for Triferic AVNU. The Company will be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million . The Company is entitled to make interest-only payments for thirty months , or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75% , plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9% . The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended March 31, 2020 and 2019 , interest expense amounted to $80,907 and nil , respectively. The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020, or September 30, 2020 if the Company draws the second tranche of $5.0 million . As of March 31, 2020 , we were in compliance with all the reporting and financial covenants. In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5 -trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5 -trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company’s common stock at an exercise price of $1.65 per share. As of March 31, 2020, the outstanding balance of the Term Loan was $20.7 million , net of unamortized issuance costs and unaccreted discount of $1.8 million . The following table reflects the schedule of principal payments on the Term Loan as of March 31, 2020: Principal Payments 2020 $ — 2021 — 2022 2,250,000 2023 9,000,000 2024 9,000,000 2025 2,250,000 $ 22,500,000

Deferred Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Deferred Revenue	Deferred Revenue In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $20 million . The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $0.5 million for the three months ended March 31, 2020 and 2019 . Deferred revenue related to the Baxter Agreement totaled $8.6 million as of March 31, 2020 and $9.1 million as of December 31, 2019 . If a “Refund Trigger Event” occurs under the Baxter Agreement, we would be obligated to repay a portion of the upfront fee and any paid portion of the facility fee. In the event of a Refund Trigger Event occurring from April 1, 2020 to December 31, 2021, Baxter would be eligible for a 25% refund of the Baxter Agreement’s upfront fee. In addition, if Baxter terminates the Baxter Agreement because Baxter has been enjoined by a court of competent jurisdiction from selling in the United States any product covered by the Baxter Agreement due to a claim of intellectual property infringement or misappropriation relating to such product prior to the end of 2020 , Baxter would be eligible for a partial refund of the upfront fee of $6.6 million . In no event does the Baxter Agreement require more than one refund be paid. In 2016 , the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million . The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million for the three months ended March 31, 2020 and 2019 . Deferred revenue related to the Wanbang Agreement totaled $2.9 million as of March 31, 2020 and $3.0 million as of December 31, 2019 . On January 14, 2020, we entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic Dialysate (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic Dialysate in India, and we will supply the product to Sun Pharma. In consideration for the license, we received an upfront fee of $0.1 million , and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic Dialysate in India. Sun Pharma will be responsible for all clinical, regulatory and commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 during the three months ended March 31, 2020 .

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock As of March 31, 2020 and December 31, 2019 , there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and no shares of preferred stock issued or outstanding. Common Stock As of March 31, 2020 and December 31, 2019 , there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 69,049,102 and 65,378,890 shares issued and outstanding, respectively. Controlled Equity Offering (or "At the Market" Offering) On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018, the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019. Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an “at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time. During the year ended December 31, 2019, the Company sold 1,840,443 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $5,383,079 , at a weighted average selling price of approximately $2.92 . The Company paid $309,479 in commissions and offering fees related to the sale of the common stock. As of March 31, 2020 , approximately $34,616,921 remains available for sale under this facility. We are not required to sell any shares at any time during the term of the facility. Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things. Public Offering of Common Stock On February 4, 2020 , the Company entered into an underwriting agreement with Cantor Fitzgerald & Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to 3,670,212 shares of its common stock, which included 478,723 optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February 6, 2020 , the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the "Offering"). On February 19, 2020 , the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February 21, 2020 . The Company raised a total of $8.0 million , net of an estimated issuance costs of $0.1 million , relating to the sale of the common stock in the Offering. The Offering was made pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Company recognized total stock-based compensation expense during the three months ended March 31, 2020 and 2019 as follows: Three Months Ended 2020 2019 Service based awards: Restricted stock units $ 238,115 $ 344,351 Stock option awards 439,625 652,024 677,740 996,375 Performance based awards: Restricted stock units 171,210 398,388 Stock option awards 85,897 122,539 257,107 520,927 Total $ 934,847 $ 1,517,302 Restricted Stock A summary of the Company’s restricted stock awards during the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2020 146,800 $ 5.70 Unvested at March 31, 2020 146,800 $ 5.70 A summary of the Company’s restricted stock awards during the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 146,800 $ 5.70 Unvested at March 31, 2019 146,800 $ 5.70 The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months . As of March 31, 2020 unvested restricted stock awards of 146,800 were related to performance based awards. Service Based Restricted Stock Units A summary of the Company’s service based restricted stock units during the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 463,786 4.26 Granted 16,304 2.61 Forfeited (7,460 ) 4.15 Unvested at March 31, 2020 472,630 4.21 A summary of the Company’s service based restricted stock units during the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 472,959 $ 4.32 Unvested at March 31, 2019 472,959 $ 4.32 The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years . Stock-based compensation expense of $0.2 million and $0.3 million was recognized during the three months ended March 31, 2020 and 2019 , respectively. As of March 31, 2020 , the unrecognized stock-based compensation expense was $0.7 million , which is expected to be recognized over an estimated weighted average remaining term of 1 year . Performance Based Restricted Stock Units A summary of the Company’s performance based restricted stock units during the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 988,958 $ 4.48 Unvested at March 31, 2020 988,958 $ 4.48 A summary of the Company’s performance based restricted stock units during the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 988,958 $ 4.48 Unvested at March 31, 2019 988,958 $ 4.48 Stock-based compensation expense recognized for performance based restricted stock units was $0.2 million and $0.4 million during the three months ended March 31, 2020 and 2019 , respectively. As of March 31, 2020 , the unrecognized stock-based compensation expense related to performance based restricted stock units was $0.7 million , which is expected to be recognized over an estimated weighted average remaining term of 2 years . . Service Based Stock Options The fair value of the service based stock options granted for the three months ended March 31, 2020 were based on the following assumptions: March 31, Exercise price $2.00 - $2.90 Expected stock price volatility 68.2% - 73.8% Risk-free interest rate 0.4% - 1.67% Term (years) 5.5 -6.5 A summary of the Company’s service based stock option activity for the three months ended March 31, 2020 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2020 8,210,024 $ 7.06 5.1 $ 107,150 Granted 51,148 $ 2.30 9.9 $ — Forfeited (457,334 ) $ (7.02 ) — $ — Outstanding at March 31, 2020 7,803,838 $ 7.03 5.1 $ 1,950 Exercisable at March 31, 2020 6,146,337 $ 7.97 4.1 $ — A summary of the Company’s service based stock option activity for the three months ended March 31, 2019 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2019 7,856,480 $ 7.50 5.2 $ — Granted 75,000 $ 3.49 9.8 Exercised (30,000 ) $ 4.93 — Outstanding at March 31, 2019 7,901,480 $ 7.47 5.0 $ 1,959,736 Exercisable at March 31, 2019 6,707,693 $ 8.05 4.2 $ 206,872 The aggregate intrinsic value in the table above is calculated as the difference between the closing price of our common stock and the exercise price of the stock options that had strike prices below the closing price. During the three months ended March 31, 2020 , the Company granted stock options to purchase up to 51,148 shares of common stock to certain employees. During the three months ended March 31, 2020 , 457,334 shares were forfeited. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly. Stock-based compensation expense recognized for service based stock options was $0.4 million and $0.7 million for the three months ended March 31, 2020 and 2019 , respectively. As of March 31, 2020 , total stock-based compensation expense related to unvested options not yet recognized totaled approximately $1.7 million , which is expected to be recognized over an estimated weighted average remaining term of 1.2 years . Performance Based Stock Options A summary of the performance based stock options for the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2020 388,125 $ 4.70 Outstanding at March 31, 2020 388,125 $ 4.70 Exercisable at March 31, 2020 — $ — A summary of the performance based stock options for the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2019 388,125 $ 4.70 Outstanding at March 31, 2019 388,125 $ 4.70 Exercisable at March 31, 2019 — $ — Stock-based compensation expense recognized for performance based stock options was $0.1 million for the three months ended March 31, 2020 and 2019 . As of March 31, 2020 , the unrecognized stock-based compensation expense related to performance based stock options was $0.4 million . On April 17, 2020, Stuart Paul resigned as Chief Executive Officer of the Company, effective immediately. The effects of his resignation are discussed in Note 18 below. The tables above are as of March 31, 2020 and do not reflect Mr. Paul's resignation. All changes relating to his resignation will be reflected in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Product License Agreements The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, who serves as Executive Vice President and Chief Scientific Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak, as well as the Employment Agreement (defined below). The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in four quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company recorded $1.1 million as Research and Development Expense - License Acquired (Related Party) for the twelve months ended December 31, 2018 . The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December 31, 2019 . As of March 31, 2020 and December 31, 2019 , the Company accrued $27,500 and $0.1 million , respectively, as a related party payable on the condensed consolidated balance sheet. Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic® (now Triferic AVNU), dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN”) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. The transaction was accounted for as an asset acquisition pursuant to ASU 2017-1, Business Combinations (Topic 805) , Clarifying the Definition of a Business, as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Charak MSA include a license of SFP. Because SFP has not yet received regulatory approval, the $1.1 million purchase price paid and accrued for these assets has been expensed in the Company’s statement of operations for the year ended December 31, 2018 . In addition, the potential milestone payments are not yet considered probable, and no milestone payments have been accrued at March 31, 2020 .

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	Leases We lease our production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of our products. The lease terms range from monthly to five years . We occupy a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2021. We also occupy two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2020, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, we occupy a 1,408 square foot office space in Greer, South Carolina under a lease expiring April 2021. In addition, we executed a lease for 4,100 square feet of office space in Hackensack, New Jersey with a lease term beginning on April 1, 2019 and expiring on July 1, 2024. At March 31, 2020 , the Company had operating lease liabilities of $2.9 million and right-of-use assets of $2.8 million , which are included in the consolidated balance sheet. The following summarizes quantitative information about the Company’s operating leases: Three Months Ended Three Months Ended March 31, 2019 Operating leases Operating lease cost $ 442,828 $ 534,967 Variable lease cost 189,283 89,844 Operating lease expense 632,111 624,811 Short-term lease rent expense 4,157 4,192 Total rent expense $ 636,268 $ 629,003 Other information Operating cash flows from operating leases $ 444,693 $ 523,965 Right of use assets exchanged for operating lease liabilities $ — $ 3,484,234 Weighted-average remaining lease term – operating leases 2.6 years 1.6 years Weighted-average discount rate – operating leases 6.8 % 6.8 % Future minimum rental payments under operating lease agreements are as follows: Year ending December 31, 2020 (remaining) $ 1,190,129 Year ending December 31, 2021 1,054,873 Year ending December 31, 2022 591,925 Year ending December 31, 2023 234,327 Year ending December 31, 2024 97,423 Total $ 3,168,677 Less present value discount (257,580 ) Operating lease liabilities $ 2,911,097

Settlement Agreement

Settlement Agreement	3 Months Ended
	Mar. 31, 2020
Settlement Agreement
Settlement Agreement	Settlement Agreement On August 7, 2018, the Company entered into a confidential settlement agreement and mutual release (the “Settlement Agreement”) with its former CEO, former CFO and a former and then current director. For more details see Note 15 in our Annual Report on Form 10-K filed on March 17, 2020. On August 7, 2019, the Company entered into a settlement agreement relating to class action lawsuits. This resulted in a settlement expense of approximately $0.4 million for the year ended December 31, 2019. See Note 16 below for further details. The terms of the settlement were approved by the court on February 26, 2020.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Demand Notice In February 2020, the Company received a letter from a supplier relating to a supply agreement entered into with the Company in 2015. The supplier alleged the Company did not meet certain annual minimums under the supply agreement, and has requested $3.0 million in penalties, plus payment of the cost for certain raw materials. Based upon current information, the Company believes it has several defenses to the supplier’s claims. No lawsuit has been filed. The Company intends to cooperate with the supplier in an effort to amicably resolve its claim. If a resolution cannot be concluded; however, the Company intends to vigorously defend itself from the supplier’s allegations. Litigation SEC Investigation As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 2019 requesting, among other things, certain information and documents relating to the status of the Company’s request to the Centers for Medicare & Medicaid Services (the "CMS") for separate reimbursement status for Triferic Dialysate, the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former CEO and CFO. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information. Shareholder Class Action Lawsuits On July 27, 2018, Plaintiff Ah Kit Too filed a putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and former officers, Robert Chioini and Thomas Klema (the "Too Complaint"). The Too Complaint is a federal securities class action purportedly brought on behalf of a class consisting of all persons and entities, other than Defendants, who purchased or otherwise acquired the publicly traded securities of the Company between March 16, 2018 and June 26, 2018. The Too Complaint alleges that the Company and Messrs. Chioini and Klema violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Specifically, the Too Complaint alleges that defendants filed reports with the SEC that contained purported inaccurate and misleading statements regarding the potential for the Company’s drug, Triferic, to quality for separate reimbursement status by the CMS. On September 4, 2018, Plaintiff Robert Spock filed a similar putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and Messrs. Chioini and Klema (the "Spock Complaint"). The Spock Complaint is a federal securities class action purportedly brought on behalf of a class consisting of persons who purchased the Company’s securities between November 8, 2017 and June 26, 2018. This complaint alleges that the Company and Messrs. Chioini and Klema violated the Exchange Act in that the Company was aware the CMS would not pursue the Company’s proposal for separate reimbursement for Triferic; misstated reserves in the Company’s quarterly report for the first quarter of 2018; had a material weakness its internal controls over financial reporting, which rendered those controls ineffective; Mr. Chioini withheld material information regarding Triferic from the Company’s auditor, corporate counsel, and independent directors of the Board; and, as a result of these alleged issues, statements about the Company’s business were materially false and misleading. On September 25, 2018, four Company stockholders filed motions to appoint lead plaintiffs, lead counsel, and to consolidate the Ah Kit Too v. Rockwell securities class action with the Spock v. Rockwell securities class action. On October 10, 2018, the court issued an order consolidating the two actions, appointing co-lead plaintiffs and co-lead counsel. On December 10, 2018, lead Plaintiffs filed a consolidated amended complaint, which included the same allegations as the initial complaints and asserted claims on behalf of a putative class consisting of person who purchased the Company’s securities between November 8, 2017 and June 26, 2018. On February 18, 2019, the Company answered the consolidated amended complaint. On August 7, 2019, all parties to the class action entered into a settlement of the consolidated class action. Pursuant to the terms and conditions of the settlement agreement, the Company will pay the Plaintiffs $3.7 million (the “Settlement Amount") in exchange for a full release of all liability as to all defendants. Of the Settlement Amount, the Company contributed approximately $0.1 million , which represented the remaining retention amount under the Company’s director and officer liability insurance policy as of March 31, 2020 . The remainder of the settlement amount will be funded by the Company’s director and officer insurance policy. The settlement was approved by the court on February 26, 2020. Shareholder Derivative Actions Plaintiff Bill Le Clair filed a Verified Stockholder Derivative Complaint on April 23, 2019 in Case No. 1:19-cv-02373, and Plaintiff John Post filed a Verified Stockholder Derivative Complaint on May 10, 2019 in Case No. 1:19-cv-02774 (the “Derivative Complaints”) in the United States District Court in the Eastern District of New York, purportedly on behalf of the Company (as nominal defendant) and against certain of the Company’s current and former directors (the “Individual Defendants”). The Derivative Complaints assert causes of actions against the Individual Defendants for breach of fiduciary duty, waste of corporate assets, and unjust enrichment. The Derivative Complaints allege the Individual Defendants breached duties by, among other things, permitting alleged misstatements to be made in public filings regarding the status of separate reimbursement for Triferic from CMS, the adequacy of the Company's reserves and internal controls. The Derivative Complaints demand a jury trial, seeking monetary damages, corporate governance and internal procedure reform, injunctive relief on the Individual Directors’ trading activities, restitution, and attorneys’ fees. The cases have been consolidated and the parties are in advanced settlement discussions. If a settlement is not reached, the Defendants anticipate filing motions to dismiss. The Company has tendered the above shareholder derivative actions to its director and officer insurance carrier(s) for defense and indemnity under its applicable insurance policies. The Company maintains a $1.0 million self-insured retention under the applicable insurance policies, which will be exhausted upon payment of the Company’s share of the Settlement Amount from the settlement of the class action described above.

Loans and Security Agreement

Loans and Security Agreement	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Loans and Security Agreement	Insurance Financing Note Payable On June 3, 2019, the Company entered into a short-term note payable for $1.9 million , bearing interest at 4.65% per annum to finance various insurance policies. Principal and interest payments related to this note will begin on July 3, 2019 and are paid on a straight-line amortization over a 10 -month period with the final payment due on April 3, 2020. As of March 31, 2020 , the Company’s insurance note payable balance was $0.2 million . Loan and Security Agreement On March 16, 2020 , Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including the FDA approval of the Company’s New Drug Application for Triferic AVNU. The Company will be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million . The Company is entitled to make interest-only payments for thirty months , or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75% , plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9% . The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended March 31, 2020 and 2019 , interest expense amounted to $80,907 and nil , respectively. The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020, or September 30, 2020 if the Company draws the second tranche of $5.0 million . As of March 31, 2020 , we were in compliance with all the reporting and financial covenants. In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5 -trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5 -trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company’s common stock at an exercise price of $1.65 per share. As of March 31, 2020, the outstanding balance of the Term Loan was $20.7 million , net of unamortized issuance costs and unaccreted discount of $1.8 million . The following table reflects the schedule of principal payments on the Term Loan as of March 31, 2020: Principal Payments 2020 $ — 2021 — 2022 2,250,000 2023 9,000,000 2024 9,000,000 2025 2,250,000 $ 22,500,000

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Resignation of President and Chief Executive Officer and Director On April 17, 2020, Stuart Paul resigned as the President and Chief Executive Officer of the Company and as a member of the board of directors of the Company (the “Board”) effective immediately. As a result of Mr. Paul’s resignation and the previously disclosed decision by Lisa Colleran not to stand for reelection at the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”), the size of the Board will be reduced to five directors effective as of the Annual Meeting. As a result of Mr. Paul’s resignation, certain time-based, all performance-based and all market-based stock awards previously granted to Mr. Paul will be forfeited. Such forfeitures will be reflected in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. The estimated expense reduction in stock compensation expense related to the forfeited stock awards is approximately $2.4 million . Appointment of President and Chief Executive Officer On April 17, 2020, the Board appointed Russell H. Ellison, M.D., M.Sc. as the Company’s President and Chief Executive Officer effective immediately. Dr. Ellison has served as a member of the Board since January 2020. He will continue to serve as a Class III Director but has resigned as a member of the Compensation Committee. On April 17, 2020, in connection with Dr. Ellison’s commencement of employment, the Company entered into an employment agreement with Dr. Ellison pursuant to which he will serve as the Company’s President and Chief Executive Officer (the “Employment Agreement”). The Employment Agreement provides that Dr. Ellison will serve as an at-will employee. Dr. Ellison will receive an annualized base salary of $500,000 (“Base Salary”) and is eligible for a one-time performance-based bonus of $500,000 upon the achievement of certain performance goals, as set forth in the Employment Agreement. Dr. Ellison will be eligible to earn year-end performance bonuses with a target bonus opportunity of 70% of his Base Salary (“Target Bonus”) and is eligible to participate in the employee benefit plans and programs generally available to the Company’s similarly situated senior executives. Dr. Ellison is also eligible to receive annual long-term incentive grants consistent with similar practices for the Company’s senior executives, awarded at the discretion of the Compensation Committee of the Board. In connection with his commencement of employment, he received an initial equity grant comprised of a time-based option to purchase up to 600,000 shares of the Company’s common stock (the “Initial Time-Based Options”) and a performance-based option to purchase up to 600,000 shares of the Company’s common stock (the “Initial Performance-Based Options”). The Initial Performance-Based Options are conditioned upon and subject to stockholder approval of an Amendment and Restatement of the Rockwell Medical, Inc. 2018 Long-Term Incentive Plan, which will be voted upon by the stockholders at the Annual Meeting. In the event that such stockholder approval is not obtained, the Initial Performance-Based Options will be forfeited and of no further force or effect.

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results. The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2020 or for any future interim period. The condensed consolidated balance sheet at March 31, 2020 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2019 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2019 and notes thereto included in the Company’s Annual Report on Form 10-K filed on March 17, 2020. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases	Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. The Company continues to account for leases in the prior period financial statements in accordance with ASC Topic 840.
Loss Per Share	Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same.
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of potentially dilutive securities	Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of March 31, 2020 2019 Options to purchase common stock 8,191,963 8,289,605 Unvested restricted stock awards 146,800 146,800 Unvested restricted stock units 1,461,588 1,461,917 Warrants to purchase common stock 3,248,054 — 13,048,405 9,898,322

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation Of Revenue	Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended March 31, 2020 Products By Geographic Area Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 199 $ 199 $ — License Fee – Over time 56 — 56 Total Drug Products 255 199 56 Concentrate Products Product Sales – Point-in-time 15,112 13,506 1,606 License Fee – Over time 490 490 — Total Concentrate Products 15,602 13,996 1,606 Net Revenue $ 15,857 $ 14,195 $ 1,662 Three Months Ended March 31, 2019 Products By Geographic Area Total U.S. Rest of World Drug Revenues License Fee – Over time $ 68 $ — 68 Total Drug Products 68 — 68 Concentrate Products Product Sales – Point-in-time 14,996 12,923 2,073 License Fee – Over time 495 495 — Total Concentrate Products 15,491 13,418 2,073 Net Revenue $ 15,559 $ 13,418 $ 2,141
Contract Balances	The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of US dollars ($) March 31, 2020 December 31, 2019 Receivables, which are included in "Trade and other receivables" $ 4,587 $ 4,203 Contract liabilities $ 11,630 $ 12,076

Investments - Available-for-S_2

Investments - Available-for-Sale (Tables)	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Investments Available for Sale	Investments available-for-sale consisted of the following as of March 31, 2020 and December 31, 2019 : March 31, 2020 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Income Fair Value Available-for-Sale Securities Bonds $ 11,385,053 $ 22,356 $ (10,789 ) $ 59,665 $ 11,456,285 December 31, 2019 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 14,238,161 $ 13,321 $ (1,306 ) $ — $ 14,250,176

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule components of inventory	Components of inventory, net of reserves as of March 31, 2020 and December 31, 2019 are as follows: March 31, December 31, Raw Materials $ 2,750,185 $ 2,471,234 Work in Process 291,697 184,382 Finished Goods 1,873,886 1,432,290 Total $ 4,915,768 $ 4,087,906

Property And Equipment (Tables)

Property And Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of major classes of property and equipment, stated at cost	As of March 31, 2020 and December 31, 2019 , the Company’s property and equipment consisted of the following: March 31, December 31, Leasehold Improvements $ 1,175,986 $ 1,162,328 Machinery and Equipment 4,833,654 4,672,724 Information Technology & Office Equipment 1,810,246 1,810,246 Laboratory Equipment 652,676 653,075 8,472,562 8,298,373 Accumulated Depreciation (6,042,449 ) (5,864,968 ) Net Property and Equipment $ 2,430,113 $ 2,433,405

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule of accrued liabilities	Accrued liabilities as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Accrued Research & Development Expense $ 227,152 $ 283,407 Accrued Compensation and Benefits 1,920,577 1,018,196 Accrued Legal Expenses 339,606 181,597 Accrued Marketing Expenses 129,936 61,164 Other Accrued Liabilities 3,542,776 2,973,368 Total Accrued Liabilities $ 6,160,047 $ 4,517,732

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of total stock-based compensation expense	The Company recognized total stock-based compensation expense during the three months ended March 31, 2020 and 2019 as follows: Three Months Ended 2020 2019 Service based awards: Restricted stock units $ 238,115 $ 344,351 Stock option awards 439,625 652,024 677,740 996,375 Performance based awards: Restricted stock units 171,210 398,388 Stock option awards 85,897 122,539 257,107 520,927 Total $ 934,847 $ 1,517,302
Schedule of restricted stock award	A summary of the Company’s restricted stock awards during the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2020 146,800 $ 5.70 Unvested at March 31, 2020 146,800 $ 5.70 A summary of the Company’s restricted stock awards during the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 146,800 $ 5.70 Unvested at March 31, 2019 146,800 $ 5.70
Restricted stock units - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of restricted stock award	A summary of the Company’s service based restricted stock units during the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 463,786 4.26 Granted 16,304 2.61 Forfeited (7,460 ) 4.15 Unvested at March 31, 2020 472,630 4.21 A summary of the Company’s service based restricted stock units during the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 472,959 $ 4.32 Unvested at March 31, 2019 472,959 $ 4.32
Restricted stock units - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of restricted stock award	A summary of the Company’s performance based restricted stock units during the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Unvested at January 1, 2020 988,958 $ 4.48 Unvested at March 31, 2020 988,958 $ 4.48 A summary of the Company’s performance based restricted stock units during the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Unvested at January 1, 2019 988,958 $ 4.48 Unvested at March 31, 2019 988,958 $ 4.48
Stock option awards - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of stock option assumptions	The fair value of the service based stock options granted for the three months ended March 31, 2020 were based on the following assumptions: March 31, Exercise price $2.00 - $2.90 Expected stock price volatility 68.2% - 73.8% Risk-free interest rate 0.4% - 1.67% Term (years) 5.5 -6.5
Schedule of stock options activity	A summary of the Company’s service based stock option activity for the three months ended March 31, 2020 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2020 8,210,024 $ 7.06 5.1 $ 107,150 Granted 51,148 $ 2.30 9.9 $ — Forfeited (457,334 ) $ (7.02 ) — $ — Outstanding at March 31, 2020 7,803,838 $ 7.03 5.1 $ 1,950 Exercisable at March 31, 2020 6,146,337 $ 7.97 4.1 $ — A summary of the Company’s service based stock option activity for the three months ended March 31, 2019 is as follows: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2019 7,856,480 $ 7.50 5.2 $ — Granted 75,000 $ 3.49 9.8 Exercised (30,000 ) $ 4.93 — Outstanding at March 31, 2019 7,901,480 $ 7.47 5.0 $ 1,959,736 Exercisable at March 31, 2019 6,707,693 $ 8.05 4.2 $ 206,872
Stock option awards - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of stock options activity	A summary of the performance based stock options for the three months ended March 31, 2020 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2020 388,125 $ 4.70 Outstanding at March 31, 2020 388,125 $ 4.70 Exercisable at March 31, 2020 — $ — A summary of the performance based stock options for the three months ended March 31, 2019 is as follows: Number of Shares Weighted Average Outstanding at January 1, 2019 388,125 $ 4.70 Outstanding at March 31, 2019 388,125 $ 4.70 Exercisable at March 31, 2019 — $ —

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Summary of Operating Leases	The following summarizes quantitative information about the Company’s operating leases: Three Months Ended Three Months Ended March 31, 2019 Operating leases Operating lease cost $ 442,828 $ 534,967 Variable lease cost 189,283 89,844 Operating lease expense 632,111 624,811 Short-term lease rent expense 4,157 4,192 Total rent expense $ 636,268 $ 629,003 Other information Operating cash flows from operating leases $ 444,693 $ 523,965 Right of use assets exchanged for operating lease liabilities $ — $ 3,484,234 Weighted-average remaining lease term – operating leases 2.6 years 1.6 years Weighted-average discount rate – operating leases 6.8 % 6.8 %
Future Minimum Rental Payments Under Operating Leases	Future minimum rental payments under operating lease agreements are as follows: Year ending December 31, 2020 (remaining) $ 1,190,129 Year ending December 31, 2021 1,054,873 Year ending December 31, 2022 591,925 Year ending December 31, 2023 234,327 Year ending December 31, 2024 97,423 Total $ 3,168,677 Less present value discount (257,580 ) Operating lease liabilities $ 2,911,097

Loans and Security Agreement (T

Loans and Security Agreement (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of principal payments on Term Loan	The following table reflects the schedule of principal payments on the Term Loan as of March 31, 2020: Principal Payments 2020 $ — 2021 — 2022 2,250,000 2023 9,000,000 2024 9,000,000 2025 2,250,000 $ 22,500,000

Liquidity and Capital Resourc_2

Liquidity and Capital Resources (Details) - USD ($)	Mar. 16, 2020	Feb. 29, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Liquidity and Capital Resources
Cash and Cash Equivalents			$ 37,399,801		$ 11,794,526
Investments available-for-sale			11,456,285		14,250,176
Working capital net			46,100,000
Accumulated Deficit			(314,500,003)		(306,516,265)
Net cash used in operating activities			6,538,430	$ 5,423,672
Common shares sold (in shares)		3,670,212
Proceeds from the issuance of common shares		$ 8,000,000	$ 8,147,871	$ 0	$ 5,383,079
Net draw down proceeds	$ 21,200,000

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	13,048,405	9,898,322
Employee stock options
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	8,191,963	8,289,605
Restricted stock awards
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	146,800	146,800
Restricted stock units
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	1,461,588	1,461,917
Warrants
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)	3,248,054	0

Revenue Recognition - Nature of

Revenue Recognition - Nature of Goods and Services (Details)	3 Months Ended
	Mar. 31, 2020agreement
Revenue from Contract with Customer [Abstract]
Number of distribution and license agreements	3
Customers average payment term	30 days
Distributors average payment term	45 days

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Net revenue	$ 15,856,539	$ 15,559,439
Drug Product
Disaggregation of Revenue [Line Items]
Net revenue	255,000	68,000
Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	15,602,000	15,491,000
United States
Disaggregation of Revenue [Line Items]
Net revenue	14,195,000	13,418,000
United States | Drug Product
Disaggregation of Revenue [Line Items]
Net revenue	199,000	0
United States | Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	13,996,000	13,418,000
Rest of World
Disaggregation of Revenue [Line Items]
Net revenue	1,662,000	2,141,000
Rest of World | Drug Product
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	1,606,000	2,073,000
Point-in-time | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	199,000
Point-in-time | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	15,112,000	14,996,000
Point-in-time | United States | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	199,000
Point-in-time | United States | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	13,506,000	12,923,000
Point-in-time | Rest of World | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	0
Point-in-time | Rest of World | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	1,606,000	2,073,000
Over time | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000
Over time | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	490,000	495,000
Over time | United States | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	0	0
Over time | United States | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	490,000	495,000
Over time | Rest of World | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000
Over time | Rest of World | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	$ 0	$ 0

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Receivables, which are included in Trade and other receivables	$ 4,587	$ 4,203
Contract liabilities	$ 11,630	$ 12,076

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Revenue Recognition [Line Items]
Impairment losses	$ 0	$ 0
Bad-debt expense	0	$ 0
Contract assets	0		$ 0
Revenue performance obligation	11,600,000
Concentrate Products
Revenue Recognition [Line Items]
Reserve for returns	0		$ 0
Baxter Healthcare Organization
Revenue Recognition [Line Items]
Revenue performance obligation	$ 8,600,000

Investments - Available-for-S_3

Investments - Available-for-Sale (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Amortized Cost	$ 11,385,053	$ 14,238,161
Unrealized Gain	22,356	13,321
Unrealized Loss	(10,789)	(1,306)
Accrued Interest Income	59,665	0
Fair Value	$ 11,456,285	$ 14,250,176

Inventory (Details)

Inventory (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Raw Materials	$ 2,750,185	$ 2,471,234
Work in Process	291,697	184,382
Finished Goods	1,873,886	1,432,290
Total	4,915,768	4,087,906
Inventory, noncurrent	623,000	441,000
Inventory, net	4,292,768	$ 3,646,906
Triferic Inventory
Inventory [Line Items]
Raw Materials	300,000
Inventory, noncurrent	600,000
Inventory, gross	3,400,000
Inventory, reserve	2,400,000
Inventory, net	1,000,000
Triferic Dialysate
Inventory [Line Items]
Finished Goods	200,000
Triferic API
Inventory [Line Items]
Inventory, net	$ 500,000

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property and equipment
Gross property and equipment	$ 8,472,562		$ 8,298,373
Accumulated Depreciation	(6,042,449)		(5,864,968)
Net Property and Equipment	2,430,113		2,433,405
Depreciation expense	200,000	$ 200,000
Leasehold Improvements
Property and equipment
Gross property and equipment	1,175,986		1,162,328
Machinery and Equipment
Property and equipment
Gross property and equipment	4,833,654		4,672,724
Information Technology & Office Equipment
Property and equipment
Gross property and equipment	1,810,246		1,810,246
Laboratory Equipment
Property and equipment
Gross property and equipment	$ 652,676		$ 653,075

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Research & Development Expense	$ 227,152	$ 283,407
Accrued Compensation and Benefits	1,920,577	1,018,196
Accrued Legal Expenses	339,606	181,597
Accrued Marketing Expenses	129,936	61,164
Other Accrued Liabilities	3,542,776	2,973,368
Total Accrued Liabilities	$ 6,160,047	$ 4,517,732

Insurance Financing Note Paya_2

Insurance Financing Note Payable (Details) - USD ($)	Jul. 03, 2019	Mar. 31, 2020	Dec. 31, 2019	Jun. 03, 2019
Debt Disclosure [Abstract]
Short-term note payable				$ 1,900,000
Interest rate per annum				4.65%
Amortization period (in months)	10 months
Insurance financing note payable		$ 190,855	$ 763,422

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	Jan. 14, 2020	Oct. 31, 2014	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2016	Dec. 31, 2019
Deferred Revenue Arrangement [Line Items]
Deferred revenue			$ 11,630,000			$ 12,076,000
Baxter Healthcare Organization
Deferred Revenue Arrangement [Line Items]
Upfront payment		$ 20,000,000
Recognized deferred revenue			500,000	$ 500,000
Deferred revenue			$ 8,600,000			9,100,000
Refund eligible for, percent of upfront fee			25.00%
Partial refund			$ 6,600,000
Wanbang Biopharmaceutical
Deferred Revenue Arrangement [Line Items]
Upfront payment					$ 4,000,000
Recognized deferred revenue			100,000	$ 100,000
Deferred revenue			2,900,000			$ 3,000,000
Sun Pharma Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment	$ 100,000
Recognized deferred revenue			$ 2,500

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	Feb. 21, 2020	Feb. 06, 2020	Mar. 22, 2019	Feb. 29, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Feb. 19, 2020	Feb. 04, 2020
Class of Stock [Line Items]
Preferred stock, authorized (in shares)					2,000,000		2,000,000
Preferred shares, par value (in dollars per share)					$ 0.0001		$ 0.0001
Preferred shares, shares issued (in shares)					0		0
Preferred shares, shares outstanding (in shares)					0		0
Common shares, shares authorized (in shares)					170,000,000		170,000,000
Common shares, par value (in dollars per share)					$ 0.0001		$ 0.0001
Common Shares, shares issued (in shares)					69,049,102		65,378,890
Common Shares, shares outstanding (in shares)					69,049,102		65,378,890
Issuance of common stock (in shares)							1,840,443
Proceeds from the issuance of common shares				$ 8,000,000	$ 8,147,871	$ 0	$ 5,383,079
Weighted average selling price (in dollars per share)							$ 2.92
Common share issuance costs					143,913	$ 0	$ 309,479
Remaining amount available for sale					$ 34,616,921
Maximum
Class of Stock [Line Items]
Sales agreement, threshold sale of shares			$ 40,000,000
Public offering
Class of Stock [Line Items]
Issuance of common stock (in shares)		3,191,489
Proceeds from the issuance of common shares	$ 8,000,000
Common share issuance costs	$ 100,000
Common stock reserved for future issuance (up to) (in shares)									3,670,212
Share price (in dollars per share)		$ 2.22						$ 2.22
Over allotment
Class of Stock [Line Items]
Common stock reserved for future issuance (up to) (in shares)								478,723	478,723

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 934,847	$ 1,517,302
Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	677,740	996,375
Restricted stock units - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	238,115	344,351
Stock option awards - Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	439,625	652,024
Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	257,107	520,927
Restricted stock units - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	171,210	398,388
Stock option awards - Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 85,897	$ 122,539

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Awards (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested, Number of Shares (in shares)		146,800	146,800	146,800
Weighted Average Grant Date Fair Value
Unvested, Weighted Average Grant-Date Fair Value (in dollars per share)		$ 5.70	$ 5.70	$ 5.70
Vesting period	20 months
Restricted stock awards - Performance based
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested, Number of Shares (in shares)	146,800

Stock-Based Compensation - Serv

Stock-Based Compensation - Service Based Restricted Stock Units (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Weighted Average Grant Date Fair Value
Stock based compensation expenses	$ 934,847	$ 1,517,302
Restricted stock units - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period (in shares)	463,786	472,959
Granted (in shares)	16,304
Forfeited (in shares)	(7,460)
Outstanding at end of period (in shares)	472,630	472,959
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 4.26	$ 4.32
Granted (in dollars per share)	2.61
Forfeited (in dollars per share)	4.15
Outstanding at end of period (in dollars per share)	$ 4.21	$ 4.32
Stock based compensation expenses	$ 200,000	$ 300,000
Unrecognized stock-based compensation expense	$ 700,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years)	1 year
Minimum | Restricted stock units - Service based awards
Weighted Average Grant Date Fair Value
Vesting period	1 year
Maximum | Restricted stock units - Service based awards
Weighted Average Grant Date Fair Value
Vesting period	3 years

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Based Restricted Stock Units (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fair value assumptions:
Stock based compensation expenses	$ 934,847	$ 1,517,302
Restricted stock units - Performance based awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period (in shares)	988,958	988,958
Outstanding at end of period (in shares)	988,958	988,958
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 4.48	$ 4.48
Outstanding at end of period (in dollars per share)	$ 4.48	$ 4.48
Fair value assumptions:
Stock based compensation expenses	$ 171,210	$ 398,388
Unrecognized stock-based compensation expense	$ 700,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years)	2 years

Stock-Based Compensation - Se_2

Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details) - Stock option awards - Service based awards	3 Months Ended
	Mar. 31, 2020$ / shares
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 2
Expected stock price volatility	68.20%
Risk-free interest rate	0.40%
Term (in years)	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 2.90
Expected stock price volatility	73.80%
Risk-free interest rate	1.67%
Term (in years)	6 years 6 months

Stock-Based Compensation - Se_3

Stock-Based Compensation - Service Based Stock Options (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Weighted Average Exercise Price
Exercised (in dollars per share)			$ 2.92
Stock option awards - Service based awards
Shares Underlying Options
Outstanding at the beginning of the period (in shares)	8,210,024	7,856,480	7,856,480
Granted (in shares)	51,148	75,000
Exercised (in shares)		(30,000)
Forfeited (in shares)	(457,334)
Outstanding at the end of the period (in shares)	7,803,838	7,901,480	8,210,024	7,856,480
Exercisable, Shares underlying	6,146,337	6,707,693
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 7.06	$ 7.50	$ 7.50
Granted (in dollars per share)	2.30	3.49
Exercised (in dollars per share)		4.93
Forfeited (in dollars per share)	(7.02)
Outstanding at the end of the period (in dollars per share)	7.03	7.47	$ 7.06	$ 7.50
Exercise price (in dollars per share)	$ 7.97	$ 8.05
Weighted Average Remaining Contractual Term
Outstanding, Weighted Average Remaining Contractual Term	5 years 1 month 6 days	5 years	5 years 1 month 6 days	5 years 2 months 12 days
Granted, Weighted Average Remaining Contractual Term	9 years 10 months 24 days	9 years 9 months 18 days
Exercisable, Weighted Average Remaining Contractual Term	4 years 1 month 6 days	4 years 2 months 12 days
Aggregate Intrinsic Value
Outstanding (in dollars)	$ 1,950	$ 1,959,736	$ 107,150	$ 0
Intrinsic Value (in dollars)		$ 206,872

Stock-Based Compensation - Se_4

Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expenses	$ 934,847	$ 1,517,302
Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited (in shares)	457,334
Stock based compensation expenses	$ 439,625	$ 652,024
Unrecognized stock-based compensation expenses	$ 1,700,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years)	1 year 2 months 12 days
Employee stock options | Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	51,148

Stock-Based Compensation - Pe_2

Stock-Based Compensation - Performance Based Stock Options (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Weighted Average Exercise Price
Stock based compensation expenses	$ 934,847	$ 1,517,302
Stock option awards - Performance based awards
Number of Shares
Outstanding at the beginning of the period (in shares)	388,125	388,125
Outstanding at the end of the period (in shares)	388,125	388,125
Exercisable at end of period (in shares)	0	0
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 4.70	$ 4.70
Outstanding at the end of the period (in dollars per share)	4.70	4.70
Exercise price (in dollars per share)	$ 0	$ 0
Stock based compensation expenses	$ 85,897	$ 122,539
Unrecognized stock-based compensation expenses	$ 400,000

Related Party Transactions (Det

Related Party Transactions (Details)	Oct. 07, 2018USD ($)agreementinstallment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Mar. 31, 2020USD ($)	Jul. 15, 2019USD ($)	Apr. 15, 2019USD ($)	Jan. 15, 2019USD ($)	Oct. 15, 2018USD ($)
Related Party Transaction [Line Items]
Settlement expense		$ 400,000
Number of additional agreements | agreement	3
Product development and research costs			$ 1,100,000
Master services and IP agreements
Related Party Transaction [Line Items]
Payments to acquire assets			$ 1,100,000
Milestone payments				$ 0
Executive Vice President and Chief Scientific Officer
Related Party Transaction [Line Items]
Total amount due	$ 1,000,000	100,000		$ 27,500	$ 250,000	$ 250,000	$ 250,000	$ 250,000
Number of quarterly installment payments | installment	4
Installment paid		1,000,000
Related party transactions accrued reimbursement of legal expenses		$ 100,000

Leases - Narrative (Details)

Leases - Narrative (Details)	Mar. 31, 2020USD ($)ft²	Dec. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Operating lease liabilities | $	$ 2,911,097
Operating lease, right of use assets | $	$ 2,797,759	$ 3,212,530
Grapevine, Texas
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Hackensack, New Jersey
Lessee, Lease, Description [Line Items]
Facility sqft.	4,100
Lease facility one | Wixom, Michigan
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Lease facility one | Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	57,000
Lease facility two | Wixom, Michigan
Lessee, Lease, Description [Line Items]
Facility sqft.	17,500
Lease facility two | Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	1,408
Minimum
Lessee, Lease, Description [Line Items]
Lease term	1 month
Maximum
Lessee, Lease, Description [Line Items]
Lease term	5 years

Leases - Summary of Operating L

Leases - Summary of Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	$ 442,828	$ 534,967
Variable lease cost	189,283	89,844
Operating lease expense	632,111	624,811
Short-term lease rent expense	4,157	4,192
Total rent expense	636,268	629,003
Operating cash flows from operating leases	444,693	523,965
Right of use assets exchanged for operating lease liabilities	$ 0	$ 3,484,234
Weighted-average remaining lease term – operating leases	2 years 7 months 6 days	1 year 7 months 6 days
Weighted-average discount rate – operating leases	6.80%	6.80%

Leases - Future Minimum Rental

Leases - Future Minimum Rental Payments Under Operating Leases (Details)	Mar. 31, 2020USD ($)
Leases [Abstract]
Year ending December 31, 2020 (remaining)	$ 1,190,129
Year ending December 31, 2020	1,054,873
Year ending December 31, 2021	591,925
Year ending December 31, 2022	234,327
Year ending December 31, 2023	97,423
Total	3,168,677
Less present value discount	(257,580)
Operating lease liabilities	$ 2,911,097

Settlement Agreement (Details)

Settlement Agreement (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Settlement Agreement
Settlement expense	$ 0.4

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	Aug. 07, 2019	Feb. 29, 2020	Mar. 31, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Amount of penalties sought from supplier		$ 3
Settlement expense				$ 0.4
Self insurance retention			$ 1
Settlement agreement with all parties
Loss Contingencies [Line Items]
Litigation settlement amount	$ 3.7
Settlement expense			$ 0.1

Loans and Security Agreement Na

Loans and Security Agreement Narrative (Details)	Mar. 16, 2020USD ($)day$ / sharesshares	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Jun. 03, 2019USD ($)
Debt Instrument [Line Items]
Aggregate principal amount				$ 1,900,000
Net draw down proceeds	$ 21,200,000
Effective interest rate				4.65%
Interest expense			$ 0
Term Loan | Term Loan
Debt Instrument [Line Items]
Aggregate principal amount	$ 35,000,000
Interest rate, base percentage	4.75%
Interest rate, additional percentage added to base percentage	4.00%
Initial interest rate percentage	8.75%
Effective interest rate	10.90%
Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage	1.00%
Interest expense		$ 80,907
Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant Term Loan funded funded	3.50%
Warrant exercise price calculation, period immediately preceding execution of Loan Agreement, number of trading days | day	5
Outstanding balance, net of unamortized issuance costs and unaccreted discount		20,700,000
Unamortized issuance costs and unaccreted discount		$ 1,800,000
Term Loan | Term Loan | Minimum
Debt Instrument [Line Items]
Period for which Company is entitled to make interest-only payments	30 months
Term Loan | Term Loan | Maximum
Debt Instrument [Line Items]
Period for which Company is entitled to make interest-only payments	36 months
Term Loan | Term Loan, First Tranche
Debt Instrument [Line Items]
Aggregate principal amount	$ 22,500,000
Net draw down proceeds	21,200,000
Closing costs	$ 1,300,000
Exercise price of warrant (in dollars per share)) | $ / shares	$ 1.65
Number of shares of common stock for which warrant is exercisable (in shares) | shares	477,273
Term Loan | Term Loan, Second and Third Tranches
Debt Instrument [Line Items]
Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days | day	5
Term Loan | Term Loan, Second and Third Tranches | Maximum
Debt Instrument [Line Items]
Exercise price of warrant (in dollars per share)) | $ / shares	$ 1.65
Term Loan | Term Loan, Second Tranche
Debt Instrument [Line Items]
Aggregate principal amount	$ 5,000,000
Term Loan | Term Loan, Third Tranche
Debt Instrument [Line Items]
Aggregate principal amount	$ 7,500,000

Loans and Security Agreement -

Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) - Term Loan - Term Loan	Mar. 31, 2020USD ($)
Debt Instrument [Line Items]
2020	$ 0
2021	0
2022	2,250,000
2023	9,000,000
2024	9,000,000
2025	2,250,000
Principal Payments	$ 22,500,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent event	Apr. 17, 2020USD ($)directorshares
Subsequent Event [Line Items]
Number of directors Board will be reduced to, effective as of Annual Meeting | director	5
Estimated expense reduction in stock compensation expense related to forfeited stock awards	$ 2,400,000
Chief Executive Officer
Subsequent Event [Line Items]
Annualized base salary	500,000
One-time performance-based bonus	$ 500,000
Target bonus opportunity, percent of Base Salary	70.00%
Initial Time-Based Options | Chief Executive Officer
Subsequent Event [Line Items]
Equity grant received (in shares) | shares	600,000
Initial Performance, Based Options | Chief Executive Officer
Subsequent Event [Line Items]
Equity grant received (in shares) | shares	600,000